Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.78 USD

73.78
5,148,046

-0.56 (-0.75%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Andrew Rocco headshot

Mind the Gap: Understanding the 3 Types of Price Gaps

Large price gaps can mark the end of a major price moves or be the signature of a future winning stock. Andrew Rocco explains the difference through historical examples.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.

Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL

Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.

Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

Gilead (GILD) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others

Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Gilead (GILD) Might Surprise This Earnings Season

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Why Gilead (GILD) is Poised to Beat Earnings Estimates Again

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

Style Box ETF report for DVY

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.

Gilead (GILD) to Report Q4 Earnings: What's in the Cards?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.

GILD or GMAB: Which Is the Better Value Stock Right Now?

GILD vs. GMAB: Which Stock Is the Better Value Option?

Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?

Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

Style Box ETF report for ONEY